Hot Investor Mandate 2: Corporate VC Seeks Therapeutics In Oncology, Regenerative Medicine, Inflammatory, and Immune Disorders

The corporate venture arm of a large global pharmaceutical company seeks to make strategic investments into early-stage companies that are aligned with the parent firm’s R&D focus. For equity investments, the firm prefers to maintain <15% equity stake in the company, and participate in rounds where lead investors include VC firms or other institutional investors. The venture arm is able to contribute additional non-dilutive resources that can increase the probability of successful product and business development. The group maintains a flexible approach to all investment opportunities. The group seeks to make investments of up to $5M, and usually targets 3-4 investments per year.

The firm’s core focus is on therapeutics, but is also open to invest in improved efficiencies in drug discovery & development, new platforms for target and drug discovery, drug delivery and is beginning to look into digital health solutions that fall within the company’s main R&D focus areas. Currently, the firm is most interested in chronic inflammatory and immune disorders (particularly for gastrointestinal diseases), oncology, regenerative medicine and vaccines; not currently as interested in cardiovascular or CNS indications. The firm does not invest in traditional medical devices or diagnostics. Although the firm is just beginning to explore digital health/health IT, the firm would be open to evaluating healthcare-related software platforms, wearable for health monitoring or digital, companion diagnostics (digital solutions that complement traditional therapeutics).

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm is open to follow-on rounds of investment where they assist in driving promising projects to fruition, and strategic alignment of the investment remains true. The firm respects the autonomy of the institutions it invests in, and will usually seek passive investment terms, providing strategic management input only when requested. However, the firm will require board observer rights and will usually request scientific review rights when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Mid-Atlantic VC Seeks HCIT, Diagnostics and Life Science Tools

A venture capital fund founded in 1992 and based in the US Mid-Atlantic region focuses on healthcare IT and diagnostics. The firm primarily invests in the growth stage at the series A or B round, though if investing early, the firm would be part of a syndicate. The firm typically invests around $1M-$15M into early companies, and $10M-$30M into growth stage companies. The firm seeks to make 10-15 new investments within the next year. The firm focuses on companies based in USA and Canada due to practical matters, though may be open to investments on a global level.

The firm has a primary focus in healthcare IT, particularly in EMR companies, analytics, and any next generation IT tools for enterprise or ambulatory settings. The firm’s secondary focus is in tools and diagnostics, specifically in 510K genomics diagnostics, though is open to any kind of new diagnostic tool or test. The firm currently does not have interest in therapeutics or medical technology. The firm prefers companies with a commercialized product that is producing revenue, though does not have a revenue requirement and may be open to clinical stage products.

The firm primarily invests in growth stage companies where 80% of their invested companies have revenue with a product looking to expand in the market and 20% of invested companies at the pre-revenue, close to commercialization stage. The firm typically invests in pre-revenue companies when the technology is close to commercialization (i.e. steps away from approval) and/or when the company has a strong management team with members the firm has known from before. The firm does not have a management team requirement and will take a board seat depending on the size and ownership of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: European Firm Raises New Fund for Innovative Therapeutics, Medtech, Diagnostics

An investment firm based in Europe that provides private equity financing to early- and mid-stage human healthcare and life science companies has raised a new €100 million fund that closed in March 2016. The firm can allocate up to €7M (in equity) per company, always co-investing with other specialized investors and during the whole life of the investment. The firm looks for companies that are based in Europe or the US.

The firm invests in innovative therapeutics, medtech and diagnostics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. For therapeutics, the firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have a solid animal data. For medical devices, the firm is also opportunistic and looks for devices that have a working prototype.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

How Massachusetts Wins the War for Global Talent

By Bill Brah, Founder and Director, UMass VDC

bill

“54% of the life science companies (including MIT spinout SQZ Biotech) launched at the VDC were founded by foreign-born entrepreneurs that came to Massachusetts for graduate study and remained to launch a company. The Massachusetts Global Entrepreneur-in-Residence Program has increased their odds of getting a visa from less than 50% to 100%!”

The Venture Development Center, more commonly referred to as the “VDC” at University of Massachusetts in Boston, is an experienced community guiding startup companies from vision to launch, no strings attached. Ninety-five entrepreneurs, both from life science and technology, are currently in residence. About one-third are from UMass, while the rest are from Harvard, MIT and other universities.

It is truly a special place. Not a day goes by without learning something new from an entrepreneur. That’s because the entire VDC staff spends a lot of time listening. Listening with the goal of understanding is the key to being helpful to entrepreneurs. It’s also the precursor to discovering new opportunities to help many entrepreneurs.

Only by listening can you link together pieces of information to reveal bigger ideas to make the business ecosystem more supportive. My experience in business, university and government helps me to see connections. But it is our willingness to experiment that allows the VDC to then integrate them into something that never existed before.

Great teams are looking for an opportunity to startup

This is how the VDC came into being in 2009. (I’m Assistant Vice Provost for Research at UMass Boston, and the Founder and Director of the VDC.) We knew the city had been awash in NIH grants for decades and could see the shifting emphasis on translation (commercializing research) versus discovery. Our own university was growing in life science. Other tech transfer officers confirmed the shortage of lab space suitable for founders ready to take the tactical step from their university labs to environments where they could prove out the technology by generating the data needed to raise financing. Small, reasonable priced and well-located facilities would be a draw, despite being outside the traditional hub Kendall Square. At the end of the day scientist entrepreneurs will always choose the best value for deployment of their scarce capital.

The bargain with UMass was that I could have 18,000 square feet of hotly contested space (a former cafeteria) in the heart of the campus if our team raised the money to build startup labs and offices externally, and be financially self-sufficient. This would also serve as an example for others on campus to be more entrepreneurial. We started in 2006, and successfully raised $7.8M from five different sources to build the VDC.

We opened the VDC in 2009 at the height of the global financial crisis, when investors had taken a walk on biotech, making it challenging for new companies to get financed. However, it was still apparent that there were great teams looking for an opportunity to start. The VDC started small with only four labs and launched 13 venture backed biotech startups that eventually raised over $130M. Three months ago, one of our companies, SQZ announced a $500M deal with Roche to fight cancer with novel cell engineering technology.

Focus on global entrepreneurs

This same dedication to listening how to make the ecosystem more supportive of entrepreneurs led the VDC to jump into Massachusetts’ pioneering Global EIR Program when leaders at other universities wouldn’t.

I got a call in 2013 from Pam Goldberg of the Mass Tech Collaborative who asked if I’d join a group of heavy hitters who had been working on Mass Passport, a strategy to help startup founders get visas so they could stay after they graduate and launch their business.

Why did I eagerly volunteer to pilot and now lead the program? Because the VDC attracts science and engineering focused entrepreneurs, I had come in contact with many who came from abroad to study at our universities. 54% of the 13 life science companies (including SQZ) launched at the VDC were founded by foreign-born entrepreneurs who came to Massachusetts for graduate study and remained to launch a company. They all talked about their immigration woes.

I also understood that my own university was globalizing. Many of our students are first generation and have modest means, unable to afford to study abroad. Surrounding them with global entrepreneurs would give them a great experience, and maybe even a great job.

For their sake, I understood how vital it is for Massachusetts to win the global war for talent. A conversation years earlier, in 2010, with Iker Marcaide helped me to connect the dots. Iker graduated the previous year from the Massachusetts Institute of Technology – Sloan School of Management. He told me about his startup, peerTransfer, which helps universities streamline the processing of international tuition payments. But would UMass be willing to try the service out for itself and would any students be interested in joining the peerTransfer team?

Marcaide, a Spanish national, started the firm after being shocked by the cost of wiring fee payments from abroad. peerTransfer is solving a problem most don’t realize is a problem: it’s difficult and expensive for international college students to transfer money to pay their tuition. 55,447 currently attend a Massachusetts university, 8.2% more than in 2014.

Now called Flywire, the Boston-based company has raised $43M in venture capital, and last year doubled its revenues and headcount to 98.

Iker ended up hiring Catherine Cam, a Newton North High School grad and UMass Boston economics major. Cam worked at peerTransfer for 13 months as a Sales Operations & Marketing Intern while she completed her studies. She’s now an applications developer at Granite Communications.

Iker opened my eyes to the thousands of business, science, and engineering graduate students who attend a university in Massachusetts on an F-1 visa and desire to remain to grow a company. I also learned that Iker is a lucky one. The odds of international students like him obtaining an H-1B work visa in the national lottery after graduating are less than 50%. It is so challenging for startup founders to simply qualify that many don’t even try.

Reversing the exodus of Massachusetts most entrepreneurial grads

After the idea of an entrepreneur startup visa died in Washington, D.C., the Mass Passport group was formed. Massachusetts wanted to take matters into its own hands and increase the odds for grads like Iker. But they needed a university to step forward to use its cap-exempt status (allowing an entrepreneur to bypass the national H-1B lottery and get a cap-exempt visa) to make the program work. UMass was the only university willing to lead.

The Senate and House staff who worked on the bill to provide money for what is now known as the known as the Massachusetts Global Entrepreneur-in-Residence Program (GEIR) had no problem with engaging in regulatory competition with the feds, but wanted answers to convince their members why this was good for the state. Shouldn’t we be helping our own native born entrepreneurs? I drew on plenty of stories foreign-born entrepreneurs had told me, and pointed to what job creating machines their startups were.

Greg Bialecki, Massachusetts Secretary of Housing and Economic Development, understood the need for more evidence, as a result the VDC received funds from the Mass Tech Collaborative to pilot the program with two entrepreneurs.

Jeff Bussgang, a Flybridge partner, and the driver behind the GEIR idea, told me, we’d better find a way to add more entrepreneurs. Two entrepreneurs prove little. Even though they were his students from Harvard Business School, statistics say their companies might not survive, even though in failure, they’d become better entrepreneurs. This is a hits based business, and depends on lots and lots of trips to the plate.

So, through scrappy experimentation, Jeff and I figured out how to add more entrepreneurs without any more state money. Good thing, because the state had a budget deficit, and couldn’t make good on its $3M promise.

Last week, GEIR reached a milestone – its 10th visa. What this means is that GEIR has increased the odds of entrepreneurs graduating from our universities getting a work visa from less than 50% to 100%!

It took all of 2015 to get these 10 visas. I’ve probably spent 25% of my time on it. Each visa involves a laborious, 22 step, three-month process involving as many as nine administrators at UMass. The way the university has rallied around GEIR is impressive.

The total venture capital raised by the 10 entrepreneurs’ nine companies is $49.9M. The companies have a headcount of 137 employees. We are in process of doubling the number of entrepreneurs in 2016, with 13 already accepted. The next challenge is how to support hundreds more who want to remain after they graduate and grow a business. I think it is time other universities follow our lead.

Making the ecosystem stronger is everyone’s mission

GEIR has been transformative for the entrepreneurs and hopefully Massachusetts. We’ve written the playbook how to reverse the exodus of a group of our most important grads. Founders in California have even moved back to participate in the program!

I am proud that UMass has stepped up to the plate to make our ecosystem stronger. After all, that’s its mission as a public university.

But it should be everyone’s mission. So, let’s stop boasting about Massachusetts being the most innovative state, and instead listen more carefully how to make it the best in the world for global entrepreneurs.

RESI@TMCx Panel Announcement: Early Stage Therapeutic Investors

By Lucy Parkinson, Director of Research, LSN

Early stage therapeutics companies have a long road ahead to reach the marketplace, and will require significant investment along their way. The level of risk involved at this stage deters some investors, and much has been written about the pull-back of many venture capital firms from this phase of investment. At RESI, a panel of 5 investors who are highly experienced in investing in early stage therapeutic development will discuss how they pick winning scientfic teams and support their portfolio companies through the challenges of the development process.

Moderated by Lisa Rhoads, Managing Director, Easton Capital, the panel will feature:

This panel will give fundraising entrepreneurs a firsthand look at the strategies used by early stage therapeutic investors to assess companies at the earliest, riskiest stage of development, and will help the audience to position their companies as an attractive investment opportunity.

By registering for RESI@TMCx, you’ll be able to listen to the early stage therapeutic panel live in person, and also experience numerous opportunities to expand your network in the life sciences and to learn more about the fundraising process.

RESI-Houston-2016_600

RESI@TMCx Panel Announcement: Venture Philanthropy Investors

By Christine A. Wu, Research Analyst, LSN

chrsitine

Venture philanthropy organizations provide more than just financing. Often times, these investors can provide a network of experts, patients, and resources in their niche space. Here in Next Phase, LSN has previously covered trends in venture philanthropy investment and advice in how to approach venture philanthropy investors.

LSN is pleased to announce a panel of five investors in the venture philanthropy space for RESI@TMCx on April 11th. Moderated by Jit Patel, VP of Research and Business Development of Juvenile Diabetes Research Foundation (JDRF), the panel will be joined by:

Panelists will address their specific investment criteria and unique missions; their investment decision-making process; important trends in the space; and the best approach to reach and heighten their interest.

Interested in this panel? It’s not too late to register for RESI@TMCx Houston and see this panel live. View the full RESI@TMCx agenda here. You can also view a video recap of our RESI San Francisco Venture Philanthropy session.

RESI-Houston-2016_600

Hot Investor Mandate 1: Family Office Seeks Therapeutics, Cancer Diagnostics & PMA Devices with Clinical Data

A family office based in Australia focuses on late stage therapeutics and medical devices that are past pre-clinical trials. Currently manages a $2.5 billion evergreen fund, and typically invests between $1 and $10 million. The firm normally makes co-investments in the USA, Europe, Israel, and Australia.

The firm is currently looking for new investment opportunities in therapeutics and PMA medical devices. The firm is only interested in later stage technology at Phase II or later, and is particularly interested in peripheral blood-based colorectal cancer diagnostics. The firm is open to all subsectors and indications in therapeutics and medical devices, though is not interested in software-enabled devices or lab equipment and drug development enabling technology. The firm does not invest in pre-clinical products, and only seeks products that are either in clinical trials (Phase II or later) with human data or on-the-market.

The firm seeks companies with an established management team with experience in the field. The firm does not typically take a board seat after an investment. The firm seeks distribution rights for Australia and Southeast Asia from international companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com